Korean Post-marketing Surveillance for Onglyza®

Study identifier:CV181-171

ClinicalTrials.gov identifier:NCT01575483

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Korean Post-marketing Surveillance for Onglyza®

Medical condition

Diabetes Mellitus, Type 2

Phase

Healthy volunteers

Study drug

No Intervention (subjects were previously treated with Onglyza®)

Sex

All

Actual Enrollment

3433

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Mar 2012

Primary Completion Date: 07 Sept 2016

Study Completion Date: 07 Sept 2016

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2017 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Seoul, Republic of Korea

Arms	Assigned Interventions
Patients with T2DM Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled	Drug: No Intervention (subjects were previously treated with Onglyza®) No Intervention Other Name: saxagliptin

"There is no result for the study"

Documents available

FDA Safety Alerts and Recalls
Download
CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Bristol-Myers Squibb

Korean Post-marketing Surveillance for Onglyza®

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Documents available

FDA Safety Alerts and Recalls

CSR Synopsis

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator